Clinical trials · New York
Obesity & Overweight clinical trials in New York
We’re tracking 45 recruiting obesity & overweight studies with a site in New York — including Phase 2, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT07595549RecruitingPhase 3
Testing Berobenatide for Weight Loss in Overweight Adults
This study tests a new medicine called berobenatide to help people with overweight or obesity lose weight. The medicine may also help improve related health conditions like high blood pressure, high cholesterol, or type 2 diabetes.
New York, New YorkAges 18 years+ - NCT05770570RecruitingPhase 2
Diet and activity texting support for Mexican American drivers
This Phase 2 study tests a structured program using texts and recordings to help people improve diet and physical activity for weight loss. It focuses on specific Spanish-speaking groups and also includes a separate track for taxi/FHV drivers.
New York, New YorkAges 21 years+ - NCT07589608RecruitingPhase 2
Weight Loss Study With Two New Injectable Medications
This study tests two new injectable drugs (macupatide and eloralintide) alone or together to help adults with obesity or excess weight lose weight. The goal is to see if these medications are safe and effective for weight management.
Amherst, New YorkAges 18–75 - NCT06143956RecruitingPhase 2
Weight loss treatments for adults with obesity
This clinical trial tests new treatments for adults who are overweight or have obesity. The goal is to help people lose weight and improve their health.
Amherst, New YorkAges 18–75 - NCT06672549RecruitingPhase 3
Weight loss medication study for children with obesity
This trial tests a medication for children and teens with obesity or overweight who have not been able to lose enough weight with diet and exercise alone. It aims to see if a new treatment can help them safely lose weight and improve related health problems.
Buffalo, New YorkAges 6–17 - NCT07353931RecruitingPhase 3
Study of eloralintide for knee osteoarthritis pain in people with overweight or obesity
This trial tests an investigational drug called eloralintide to see if it can reduce knee pain in people with osteoarthritis who also have overweight or obesity. You may be able to join if you have knee osteoarthritis, a BMI of 27 or higher, and have tried to lose weight with diet before.
Brooklyn, New YorkAges 18 years+ - NCT07685808RecruitingPhase 2
Testing a weight loss injection for people with overweight or obesity
This study tests an injectable medication called Olatorepatide to help people with overweight or obesity lose weight. It is only for people without diabetes who meet specific body mass index (BMI) requirements.
New York, New YorkAges 18 years+ - NCT07369011RecruitingPhase 3
Study of eloralintide for sleep apnea with obesity
This study tests an investigational medication called eloralintide to see if it can improve sleep apnea in people who are overweight or have obesity. You will receive either the study drug or a placebo (inactive shot), and your sleep and weight will be monitored over time.
Buffalo, New YorkAges 18 years+ - NCT07037433RecruitingPhase 3
Heart protection study for people with heart disease and overweight
This study tests a new weekly injection (maridebart cafraglutide) to see if it helps lower the risk of heart problems in people with heart disease and overweight. It is for adults who have had a heart attack, stroke, or artery blockages and also have a BMI of 27 or higher.
Binghamton, New YorkAges 45–99 - NCT07575399RecruitingPhase 3
Switching to a New Weight-Loss Medication From Current GLP-1
This trial tests whether switching from your current GLP-1 medication (like Ozempic or Wegovy) to a new drug called maridebart cafraglutide works as well or better for weight management. You must have already lost at least 10% of your body weight on your current GLP-1 and be doing well with it.
New York, New YorkAges 18–99 - NCT06937099RecruitingPhase 3
Testing two drugs for Crohn's with weight issues
This trial tests two study drugs, mirikizumab and tirzepatide, in people with moderate to severe Crohn's disease who also have overweight or obesity. The goal is to see if these treatments can help control Crohn's symptoms and inflammation.
New York, New YorkAges 18–70 - NCT07743450RecruitingPhase 3
Daily oral medication for weight loss in adults with obesity and type 2 diabetes
This study tests a once-a-day pill for adults who are overweight or have obesity and also have type 2 diabetes. The goal is to see if the medication helps with weight loss and improves blood sugar control.
East Northport, New YorkAges 18 years+ - NCT07321886RecruitingPhase 3
Study of eloralintide for people with obesity or overweight
This trial tests if an investigational drug called eloralintide can help people with obesity or overweight lose weight. It is for people who do not have type 2 diabetes and who have tried but struggled to lose weight on their own.
Rochester, New YorkAges 18 years+ - NCT07282600RecruitingPhase 3
Study of eloralintide for type 2 diabetes and weight
This study tests a new medicine called eloralintide for people with type 2 diabetes who are overweight or have obesity. It aims to see if the drug can help with weight loss and blood sugar control.
Long Island City, New YorkAges 18 years+ - NCT07351045RecruitingPhase 3
Study of enicepatide for weight loss in obesity or overweight
This study tests a new injectable medication called enicepatide for people with obesity or overweight who have not been able to lose weight through diet and exercise alone. It may help you lose weight and improve health conditions linked to excess weight.
Buffalo, New YorkAges 18 years+ - NCT07752979RecruitingPhase 2
New drug for weight loss in adults with obesity or overweight
This study tests an investigational drug called ABBV-295 to see if it helps adults with obesity or overweight who have weight-related health conditions lose weight. It may offer a new treatment option for managing weight and improving overall health.
Rochester, New YorkAges 18–75 - NCT07743463RecruitingPhase 3
Daily pill for weight loss in adults with excess weight or weight-related health issues
This study tests a once-daily pill called ASC30 to help adults with obesity or overweight who also have conditions like high blood pressure, sleep apnea, or heart disease lose weight. The pill may work by affecting appetite and blood sugar, and the study aims to see how effective and safe it is.
New Windsor, New YorkAges 18 years+ - NCT06937086RecruitingPhase 3
Mirikizumab plus tirzepatide for UC with obesity
This study tests whether adding mirikizumab to the weight-loss drug tirzepatide helps people with moderate-to-severe ulcerative colitis who also have obesity or overweight. It aims to see if the combination reduces bowel inflammation and helps with weight management.
New York, New YorkAges 18–70 - NCT07654374RecruitingPhase 3
Study of a new pill for weight loss and diabetes
This study tests a new daily pill (aleniglipron) to help adults with excess weight and type 2 diabetes lose weight and improve blood sugar control. It may be a good fit if you have a BMI of 27 or higher and your diabetes is managed with A1c between 6.5% and 10%.
Albany, New YorkAges 18–79 - NCT07794579RecruitingPhase 3
Study of orforglipron for people with overweight at risk of health problems
This trial tests a new medicine, orforglipron, to help people with overweight who are at risk of developing weight-related health issues. It aims to see if the medicine can help with weight management and reduce risks before more serious conditions develop.
Hartsdale, New YorkAges 18 years+ - NCT07654361RecruitingPhase 3
A new pill for weight loss in obesity and overweight
This study tests an investigational pill called aleniglipron to see if it helps people with obesity or overweight who also have a weight-related health problem (like high blood pressure) lose weight safely. It is a Phase 3 trial, meaning it is in the final stages before seeking approval.
Albany, New YorkAges 18–79 - NCT06857942RecruitingPhase 4
Tirzepatide added to ixekizumab for psoriasis and weight issues
This trial tests whether adding tirzepatide (a weight-loss and diabetes drug) to ixekizumab (a psoriasis treatment) helps people with moderate-to-severe psoriasis who are overweight or have obesity. It is for those already taking ixekizumab for about 3 months.
New York, New YorkAges 18 years+ - NCT07784725RecruitingPhase 3
Study of a weight loss injection for adults with obesity
This study tests a new medicine to help adults with obesity or overweight lose weight. It's for people who have had trouble losing weight in the past and don't have diabetes.
Cortland, New YorkAges 18 years+ - NCT07090005Recruiting
Endoscopic weight loss: comparing EndoZip and Apollo ESG
This study compares two different endoscopic procedures (EndoZip and Apollo ESG) to help obese patients lose weight. Both are done through the mouth without cutting the skin, and the goal is to see which works better and is safer.
New York, New YorkAges 21–65
Obesity & Overweight trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting obesity & overweight studies listed above.
- Rochester Clinical Research · 7 studies
- Rochester Clinical Research, LLC · 6 studies
- NYC Research INC · 3 studies
- Care Access - Yonkers · 2 studies
- Dent Neurologic Institute · 2 studies
- Icahn School of Medicine at Mount Sinai / Mount Sinai Hospital · 2 studies
- New York Gastroenterology Associates · 2 studies
- ACCOMPLISH-1 Research Site
What taking part in a obesity & overweight study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Obesity & Overweight trials in other states
Common questions
- Are there obesity & overweight clinical trials in New York?
- Yes. We're currently tracking 45 recruiting obesity & overweight studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a obesity & overweight study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a obesity & overweight trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New obesity & overweight studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.